Right Turn: Stem Cell Diabetes Treatment Looking Sweet

Author: Stacey Johnson, 07/25/14

. It’s nice to end the week on a happy note. For a company like CCRM that commercializes regenerative medicine products and therapies, the news that ViaCyte, a company based in San Diego, California, has applied to the FDA to start clinical trials for its Type 1 diabetes treatment is good news for the industry….Read more

Highlights from The Business of Regenerative Medicine Course

Author: Mark Curtis, 07/21/14

. The Centre for Commercialization of Regenerative Medicine (CCRM) just finished hosting the 7th annual Business of Regenerative Medicine course here in Toronto, which saw many notable figures in the space come to weigh-in on a number of critical issues relevant to commercialization in the world of regenerative medicine and cell therapy (RM).   The…Read more

Right Turn: Nailed it! The making of a stem cell exhibit

Author: Lisa Willemse, 07/18/14

A few months ago, I mentioned that we were involved in the creation of a traveling science exhibit with a number of great partners, and introduced one of the fictional characters, the “Regenerator”, who will be appearing as one of our stem cell superheroes. A lot has happened in the three months, and the exhibit,…Read more

Old tissue, new purpose: DISCUSSing consent and iPSC derivation

Author: Lisa Willemse, 07/14/14

Written with contributions from Geoff Lomax, CIRM’s Senior Officer for Medical and Ethical Standards and Rosario Isasi, Research Associate at McGill University and Academic Secretary for the International Stem Cell Forum Ethics Working Party. Portions of this post were previously published on the CIRM Research Blog and are included here with consent. It’s not unusual…Read more

Right Turn: Return of Cells I See contest

Author: Stacey Johnson, 07/11/14

. Stem cells as art is becoming a recurring theme on Signals. If you want to admire some beautiful stem cell art, there’s Klair Reis’ petri projects, Radha Chaddah’s beautiful photography here, and stem cell images are featured every week on Signals near the bottom of the screen. The images in the Photo of the…Read more

Update from the Clinic: June

Author: Mark Curtis, 07/09/14

. Welcome to your Update from the Clinic for the month of June. Neuralstem presented final data on a first-in-class drug for the treatment of major depressive disorder, which is proving to be an effective and non-invasive means to boost brain volume. OncoMed has a shaky start to its Phase I programs targeting the Wnt…Read more

Tips from the grad school trenches on launching a career

Author: Sara M. Nolte, 07/07/14

> Anyone who has, or is working on, a graduate degree (e.g. PhD, MSc) has likely encountered the “what does a PhD/MSc get you?” question. In my experience, the most frustrating thing wasn’t that I was asked this question at least three times at every family gathering, but it was that I often didn’t know…Read more

Right Turn: Fire(flies) in the belly

Author: Lisa Willemse, 07/04/14

> It’s July the 4th, a date that most people, or at least Americans, equate with celebrations and fireworks. Less known in the broader world is July 1st, which happens to be Canada Day in my neck of the woods. It also features celebration and fireworks. As lovely as the fireworks were at my local community centre on…Read more

Right Turn: Wherefore art thou stem cell artists?

Author: Stacey Johnson, 06/27/14

.. CCRM’s intrepid communications summer student is back! Erin Sugar dishes on the intersection between health, art and science using an intriguing medium: the Petri plate. In the spirit of the return of the Cells I See art contest (submissions begin mid-July, 2014 – more details in a future Right Turn), this week’s blog features…Read more

Careful with the heart strings: Promise vs. potential

Author: David Kent, 06/26/14

> The cellular therapy plenary at the ISSCR conference on June 19 was an incredibly interesting mix of hope and despair. On one hand, the opening talk by Leigh Turner made us imagine thousands of people in the United States getting duped into stem cell therapies as a result of pre-mature commercialization and ethically contentious…Read more